Glenmark Pharmaceuticals Limited, an innovation‐driven global pharmaceutical company, became the first to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities.

Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities.

On the launch, Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals said, “Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities. Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities.”

Teneligliptin is a widely used DPP4i (Dipeptidyl Peptidase 4) inhibitor whereas Dapagliflozin is the most prescribed SGLT‐2i (Sodium glucose co‐transporter 2) inhibitor for diabetic patients in the country. While Zita D is a promising treatment option in managing uncontrolled Type 2 diabetes with co‐morbidities, this FDC has also proven to be effective among adult diabetic patients without comorbidities. Glenmark’s Zita D is priced at around INR 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs. 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg, per day.

According to IQVIA sales data for the 12‐month period ending Sept. 2022, the market for oral anti‐diabetic drugs in India is estimated to be Rs. 11,796 crore with an annual growth of 7% against the corresponding period last year (MAT Sept. 2021).